Axel-Sven Malkomes
Director/Board Member chez CELLECTIS S.A.
Fortune : - $ au 31/03/2024
Profil
Axel-Sven Malkomes is currently an Independent Director at Cellectis SA and a Managing Director at Medigene Immunotherapies GmbH.
Previously, he worked as Vice Chairman & MD-Life Sciences Practice at Barclays PLC from 2016 to 2019, as a Director at 3i Deutschland Gesellschaft für Industriebeteiligungen mbH, as Head-Strategy Planning at Merck KGaA, and as Global Head-Healthcare & Chemicals Investment at Société Générale SA from 2010 to 2016.
He also served as Chief Financial & Business Development Officer at MediGene AG from 2019 to 2022.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MEDIGENE AG
-.--% | 30/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Axel-Sven Malkomes
| Sociétés | Poste | Début |
|---|---|---|
| CELLECTIS S.A. | Director/Board Member | 28/06/2022 |
Medigene Immunotherapies GmbH
 Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The private company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Chief Executive Officer | - |
Anciens postes connus de Axel-Sven Malkomes
| Sociétés | Poste | Fin |
|---|---|---|
| MEDIGENE AG | Director of Finance/CFO | 31/03/2022 |
| BARCLAYS PLC | Director/Board Member | 01/03/2019 |
| SOCIÉTÉ GÉNÉRALE | Corporate Officer/Principal | 01/01/2016 |
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
 3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Private Equity Investor | 01/01/2010 |
| MERCK KGAA | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| MERCK KGAA | Health Technology |
| SOCIÉTÉ GÉNÉRALE | Finance |
| BARCLAYS PLC | Finance |
| MEDIGENE AG | Health Technology |
| CELLECTIS S.A. | Health Technology |
| Entreprise privées | 2 |
|---|---|
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Finance |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The private company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Health Technology |
